Detail akcie Hemogenyx Rg online

Business Summary: Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Hemogenyx Pharmaceuticals PLC revenues was not reported. Net loss increased 78% to L5M. Higher net loss reflects Biotechnology business segment loss increase of 82% to L4.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -L0.92 to -L1.42.